乌灵胶囊联合盐酸文拉法辛缓释胶囊治疗 脑梗死后患者躯体化症状的评价

Therapeutic efficacy of Wuling capsule combined with Venlafaxine in treatment of somatic symptoms in post-stroke patients

摘要:

目的 评价乌灵胶囊联合盐酸文拉法辛缓释胶囊治疗脑梗死后患者躯体化症状的临床疗效。方法 将68 例脑梗死后患者随机分为对照组和研究组，每组各34 例。对照组给予盐酸文拉法辛缓释胶囊治疗，研 究组给予乌灵胶囊联合盐酸文拉法辛缓释胶囊治疗。比较两组治疗前及治疗后第2、4 及6 周汉米尔顿抑郁 量表（HAMD）、汉米尔顿焦虑量表（HAMA）、健康问卷躯体症状群量表（PHQ-15）评分及治疗期间不良 反应发生情况。结果 治疗前两组HAMD、HAMA、PHQ-15 评分比较，差异无统计学意义（P >0.05）；治 疗后第2、4 及6 周研究组HAMD、HAMA 及PHQ-15 评分低于对照组（P <0.05）；两组不良反应发生率比较， 差异无统计学意义（P >0.05）。结论 乌灵胶囊联合盐酸文拉法辛缓释胶囊治疗脑梗死后患者躯体化症状的临 床疗效肯定，安全可靠。

Abstract:

Objective To investigate the therapeutic efficacy of Wuling capsule combined with Venlafaxine in treatment of somatic symptoms in post-stroke patients. Methods A total of 68 cases of post-stroke patients with somatic symptoms were randomly divided into control group (n = 34) and study group (n = 34). All patients were given Venlafaxine as standard therapy while patients in study group received additional Wuling capsule. HAMD, HAMA and PHQ-15 score were recorded prior to or 2, 4 and 6 weeks after treatment. Adverse events were identified during study. Results No statistically significant difference in HAMD, HAMA and PHQ-15 score was noticed before any treatments (P > 0.05). Patients in study group experienced significant decrease of HAMD, HAMA and PHQ-15 scores 2, 4, and 6 weeks post treatments compared with control group (P < 0.05). No obvious difference in incidence of adverse reactions was identified between two groups (P > 0.05). Conclusion Wuling capsule combined with Venlafaxine is promising for the treatment of somatic symptoms in post-stroke patients.